en · de · es · fr · pt
sr9009-notes.peptides7250.com › Info › Analytical Detection And Storage — Common Mistakes

Analytical Detection And Storage — Common Mistakes

By Editorial Desk · published 2025-10-07 · last reviewed 2025-11-14 · Info

freeze-thaw cycle comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-11-14. Numbers and descriptions here follow the published literature rather than marketing material.

Analytical Detection and Storage

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Background and Mechanism of SR9009

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Sr9009 at a glance

PropertyValueNotes
Typical storage temperature-20 °C or lowerDesiccated and protected from light
Common analytical methodLC-MS/MSDetects parent drug and metabolites
Solubility classLipophilic; soluble in organic solventsLow aqueous solubility
Molecular weight437.94 g/molCalculated from reported formula
SynonymsSR9009; REV-ERB agonistCode name used in scientific literature

Handling, Analysis, and Regulation

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.

Related pages on this site

Background from the literature

Testosterone is available for transdermal administration in the form of gels, creams, scrotal and non-scrotal patches, and axillary solutions. Transdermal testosterone gel has a bioavailability of about 8 to 14% when administered to recommended skin sites including the abdomen, arms, shoulders, and thighs. Scrotal skin is the thinnest skin of the body and has enhanced absorption characteristics relative to other skin areas. Application of testosterone gels and creams to the scrotum has been studied and achieves much higher levels of testosterone than conventional skin sites. Scrotal application of testosterone requires approximately 5-fold lower doses relative to non-scrotal application. The development of transdermal preparations of testosterone (and of progesterone) has been more difficult than the case of estradiol. This is because testosterone levels in men are about 100 to 1,000 times higher than estradiol levels in women (300 to 1,000 ng/dL vs. 50 to 150 pg/mL, respectively). Non-scrotal testosterone patches were assessed and were found to be ineffective in raising testosterone levels in men. As a result, scrotal testosterone patches were initially marketed. Subsequently, however, non-scrotal testosterone patches with special permeation enhancers that could successfully increase testosterone levels were developed and marketed. However, non-scrotal testosterone patches nonetheless require a large skin area for application (up to 60 cm2) and must be replaced daily.

=== Quantitative proteomics === A central theme of Borchers' work is the use of multiple reaction monitoring (MRM) mass spectrometry with stable isotope-labelled internal standard peptides to measure the absolute concentrations of proteins in complex biological samples such as blood plasma and tissues. His groups developed standardized, multiplexed LC-MRM assay panels for the quantitation of large numbers of proteins, characterizing them according to the assay-validation guidelines of the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC). He was among the authors of a 2009 CPTAC multi-laboratory study in Nature Biotechnology that assessed the reproducibility, dynamic range and detection limits of MRM-based protein measurements across laboratories and instrument platforms. In a 2024 study, his group and collaborators designed and validated MRM assays for the quantitation of 2,118 proteins across 20 mouse organs and tissues, releasing the assays and reference data through an open-access database called MouseQuaPro. He also worked on immuno-MALDI (iMALDI), a method that couples antibody-based enrichment of target peptides with MALDI mass spectrometry to quantify low-abundance proteins in clinical samples. He is the named inventor on a United States patent covering the underlying quantitation method, filed in 2003, granted in 2010 and assigned to the University of North Carolina at Chapel Hill.

The cells of the SA node are spread out within a mesh of connective tissue, containing nerves, blood vessels, collagen and fat. Immediately surrounding the SA node cells are paranodal cells. These cells have structures intermediate between that of the SA node cells and the rest of the atrium. The connective tissue, along with the paranodal cells, insulate the SA node from the rest of the atrium, preventing the electrical activity of the atrial cells from affecting the SA node cells. The SA node cells are smaller and paler than the surrounding atrial cells, with the average cell being around 8 micrometers in diameter and 20-30 micrometers in length (1 micrometer= 0.000001 meter). Unlike the atrial cells, SA node cells contain fewer mitochondria and myofibers, as well as a smaller sarcoplasmic reticulum. This means that the SA node cells are less equipped to contract compared to the atrial and ventricular cells. Within the node, there is a well-defined distribution of specific pacemaker cells in specific areas. In the central area of the SA node, there is a uniform distribution of the three major pacemaker cell types: cardiac pacemaker cells, atrioventricular node cells and Purkinje fibers. Atrioventricular node (AVN) cells and Purkinje fibers area latent pacemaker cells that have the capability of performing pacemaker activity. In the crista terminalis region, the atrial cells are the predominant cell type (63±18%) and are accompanied by a subset of elongated spindle nodal cells.

The Gaboon viper (Bitis gabonica), although generally docile and sluggish, has the longest fangs of any venomous snake. Their venom glands are enormous; each bite produces the largest quantities of venom of any venomous snake. Yield is probably related to body weight, as opposed to milking interval. Brown (1973) gives a venom yield range of 200–1000 mg (of dried venom), A range of 200–600 mg for specimens 125–155 cm in length has also been reported. Spawls and Branch (1995) state from 5 to 7 ml (450–600 mg) of venom may be injected in a single bite. Based on how sensitive monkeys were to the venom, Whaler (1971) estimated 14 mg of venom would be enough to kill a human being: equivalent to 0.06 ml of venom, or 1/50 to 1/1000 of what can be obtained in a single milking. Marsh and Whaler (1984) wrote that 35 mg (1/30 of the average venom yield) would be enough to kill a man of 70 kilograms (150 lb). A study by Marsh and Whaler (1984) reported a maximum yield of 9.7 ml of wet venom, which translated to 2400 mg of dried venom. They attached "alligator" clip electrodes to the angle of the open jaw of anesthetized specimens (length 133–136 cm, girth 23–25 cm, weight 1.3–3.4 kg), yielding 1.3–7.6 ml (mean 4.4 ml) of venom. Two to three electrical bursts within a space of five seconds apart were enough to empty the venom glands. The snakes used for the study were milked seven to 11 times over a 12-month period, during which they remained in good health and the potency of their venom remained the same.

=== Carbohydrate-insulin hypothesis === Low-carbohydrate diet advocates including Gary Taubes and David Ludwig have proposed a "carbohydrate-insulin hypothesis" in which carbohydrates are said to be uniquely fattening because they raise insulin levels and cause fat to accumulate unduly. The hypothesis appears to run counter to known human biology whereby there is no good evidence of any such association between the actions of insulin, fat accumulation, and obesity. The hypothesis predicted that low-carbohydrate dieting would offer a "metabolic advantage" of increased energy expenditure equivalent to 400–600 kcal(kilocalorie)/day, in accord with the promise of the Atkins diet: a "high calorie way to stay thin forever". With funding from the Laura and John Arnold Foundation, in 2012, Taubes co-founded the Nutrition Science Initiative (NuSI), with the aim of raising over $200 million to undertake a "Manhattan Project For Nutrition" and validate the hypothesis. Intermediate results, published in the American Journal of Clinical Nutrition did not provide convincing evidence of any advantage to a low-carbohydrate diet as compared to diets of other composition. This study revealed a marginal (~100 kcal/d) but statistically significant effect of the ketogenic diet to increase 24-hour energy expenditure measured in a respiratory chamber, but the effect waned over time.

Sources: en.wikipedia.org

Reference notes

In Europe the field followed its own pathway; for example in Germany the parallel interventional society began to break free of the DR society in 2008. In the UK, interventional radiology was approved as a sub-specialty of clinical radiology in 2010. While many countries have an interventional radiology society, there is also the European-wide Cardiovascular and Interventional Radiological Society of Europe, whose aim is to support teaching, science, research and clinical practice in the field by hosting meetings, educational workshops and promoting patient safety initiatives. Furthermore, the Society provides an examination, the European Board of Interventional Radiology (EBIR), which is a highly valuable qualification in interventional radiology based on the European Curriculum and Syllabus for IR.

== Awards and honours == The Indian Academy of Sciences elected Roy as their fellow in 1996 and the Council of Scientific and Industrial Research awarded him the Shanti Swarup Bhatnagar Prize, one of the highest Indian science awards, in 1999. A recipient of the Meritorious Service Award of the United States Department of Health and Human Services, he was elected by the Indian National Science Academy as a fellow in 2005. In 2007, he was elected as a fellow of the West Bengal Academy of Science and Technology and he received the J. C. Bose National Fellowship of the Science and Engineering Research Board as well as the Tata Innovation Fellowship of the Department of Biotechnology the same year. He was also a member of Guha Research Conference during the years 1992 and 2012. He is a Fellow of the Royal Society of Chemistry, UK and has been elected a member of The World Academy of Sciences (FTWAS).

This part of the County of London was transferred to the new London Borough of Newham in Outer London and Newham Council was therefore an education authority. The ILEA had a somewhat anomalous legal status. Technically the GLC itself was the education authority for inner London, but it was both administratively difficult and politically questionable to allow outer London members of the GLC to have an input. Therefore, the GLC delegated responsibility to the ILEA as a 'special committee', consisting of the members of the GLC from the Inner London area, plus one member delegated from each of the inner London boroughs and the City of London. Those who were members of both the GLC and the ILEA tended to concentrate on one duty only, although they attended the meetings of both bodies.

== Sources == Alhakim, Youssef (1983). Syria and the French Mandate (in Arabic). Beirut: Dar Al-Nahar. Bishour, Wadi' (1994). Syria: The Making of a State and the Birth of a Nation (in Arabic) (1st ed.). Damascus, Syria: Dar Al-Yaziji. Haddad, Ghassan Mohammed Rashad (2007). Shami Papers: Contemporary Syrian History 1946-1966 (in Arabic). Madbouly Library. ISBN 9789772086276. Archived from the original on 10 August 2020. Retrieved 9 February 2025. Torrey, Gordon (1964). Syrian Politics and the Military, 1945-1958. Ohio State University Press. Archived from the original on 10 August 2020.

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 measured?

Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.

How should SR9009 be stored?

Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.

What purity methods are used?

High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Network